Arnold Welden
Family Medicine · Tulare, CANPI 1699788349
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,585 and has fallen 99.0% since, to $35 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $36.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$784
- Amarin Pharma, Inc.$462
- Teva Pharmaceuticals USA, Inc.$295
- Boehringer Ingelheim$278
- GSK$265
- plus $2K from 15 others
What the payments were for
- Food & beverage$5,085100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $1,152 |
| Novo Nordisk | 23 | $784 |
| Amarin Pharma, Inc. | 21 | $462 |
| Teva Pharmaceuticals USA, Inc. | 7 | $295 |
| Boehringer Ingelheim | 10 | $278 |
| GSK | 7 | $265 |
| Merck | 11 | $261 |
| AbbVie(2 entities) | 3 | $226 |
| Abbott | 2 | $217 |
| Avanir Pharmaceuticals, Inc. | 4 | $194 |
| Amgen | 4 | $149 |
| Pfizer | 4 | $148 |
| E.r. Squibb & Sons, L.L.C. | 3 | $133 |
| Lilly USA, LLC | 3 | $132 |
| Edwards Lifesciences | 1 | $119 |
| Ironwood Pharmaceuticals, Inc | 1 | $96 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Johnson & Johnson | 3 | $49 |
| Organon | 3 | $35 |
| Mannkind Corporation | 2 | $27 |
| Shire North American Group Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,103 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 93 | $94,213 |
| OzempicSemaglutide | 70 | $76,113 |
| TrulicityDulaglutide | 67 | $64,071 |
| FarxigaDapagliflozin Propanediol | 34 | $33,369 |
| MounjaroTirzepatide | 22 | $22,654 |
| EliquisApixaban | 21 | $19,003 |
| JanuviaSitagliptin Phosphate | 20 | $18,812 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 13 | $8,993 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $8,410 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $6,877 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $5,563 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $5,458 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,228 |
| Gabapentin | 109 | $2,725 |
| Atorvastatin Calcium | 297 | $2,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Trijardy Xr, Stiolto Respimat | $278 | $108,433117 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $132 | $86,72589 claims |
| Novo NordiskOzempic | $784 | $76,11370 claims |
| AstraZenecaFarxiga | $1,152 | $33,36934 claims |
| PfizerEliquis | $148 | $19,00321 claims |
| MerckJanuvia | $261 | $18,81220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Tulare
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.